Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Quantum-Si incorporated (QSIAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: QSIAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.85% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.44B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.91 | 52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 |
52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2982.42% |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -40.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 146748948 |
Shares Outstanding - | Shares Floating 146748948 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Quantum-Si incorporated
Company Overview
History and Background
Quantum-Si incorporated was founded in 2013 with the goal of democratizing access to protein sequencing. They developed a next-generation protein sequencing platform designed to analyze proteins in a way that's more accessible and cost-effective than existing methods. They went public in 2021 via SPAC merger.
Core Business Areas
- Protein Sequencing Platform: Develops and commercializes a next-generation protein sequencing platform based on semiconductor chip technology. This platform is designed to enable researchers and clinicians to analyze proteins at single-molecule resolution, offering insights into disease biology and drug development.
Leadership and Structure
Dr. Jonathan Rothberg is the founder and chairman. The company has a typical corporate structure with a CEO, CFO, and other key executive positions overseeing various departments such as R&D, marketing, and sales.
Top Products and Market Share
Key Offerings
- Platinum: The Platinum instrument is the first next-generation protein sequencing platform using semiconductor chip technology. It is designed to analyze proteins at single-molecule resolution, and offers insights into disease biology and drug development. Competitors include traditional protein analysis methods and other emerging protein sequencing technologies.
- Consumables and Reagents: A range of consumables and reagents that are required to use the Platinum instrument. Revenue is generated from the sales of these consumables. Competitors include companies that supply reagents for traditional protein analysis methods.
Market Dynamics
Industry Overview
The protein analysis market is a large and growing market, driven by increasing demand for personalized medicine, drug discovery, and diagnostics. Next-generation protein sequencing holds significant potential to disrupt the market with its ability to provide deeper insights into protein function and disease biology.
Positioning
Quantum-Si aims to be a leader in next-generation protein sequencing, offering a platform that is more accessible, cost-effective, and provides higher resolution data compared to existing technologies. Their competitive advantage lies in their semiconductor-based platform.
Total Addressable Market (TAM)
The TAM for protein analysis is estimated to be in the tens of billions of dollars. Quantum-Si is positioned to capture a portion of this market by offering a disruptive technology that can address unmet needs in protein sequencing.
Upturn SWOT Analysis
Strengths
- Novel semiconductor-based protein sequencing technology
- Potential for high resolution and throughput
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Relatively early stage of commercialization
- Limited revenue to date
- Dependence on successful product development and market adoption
- High operating expenses
Opportunities
- Growing demand for personalized medicine and drug discovery
- Potential to expand into new applications (e.g., diagnostics)
- Strategic partnerships with pharmaceutical and research institutions
- Expansion into international markets
Threats
- Competition from established protein analysis technologies
- Emergence of alternative next-generation protein sequencing platforms
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
Competitive Landscape
Quantum-Si competes with established players in the protein analysis market that have significant resources and established customer relationships. Quantum-Si's advantage is its disruptive technology, but it faces challenges in gaining market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the early stages of commercializing its platform.
Future Projections: Future growth is dependent on successful product launches, market adoption, and expansion into new applications. Analyst estimates vary widely due to the uncertainty surrounding the company's prospects.
Recent Initiatives: Recent initiatives include the launch of the Platinum instrument, expansion of the commercial team, and development of new applications for the platform.
Summary
Quantum-Si is an early-stage company with a disruptive protein sequencing technology. While the technology shows promise, the company faces significant challenges in commercializing its platform and competing with established players. Successful execution of their strategy will be crucial for their long-term success. Quantum-Si must carefully manage its expenses and secure adequate funding to support its growth initiatives.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in early-stage companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quantum-Si incorporated
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.